Recombinant baculoviruses (rBVs) are widely used as vectors for the production of recombinant proteins in insect cells. More recently, these viral vectors have been gaining increasing attention due to their emerging potential as gene therapy vehicles to mammalian cells. Their production in stirred bioreactors using insect cells is an established technology; however, the downstream processing (DSP) of baculoviruses envisaged for clinical applications is still poorly developed. In the present work, the recovery and purification of rBVs aiming at injectable-grade virus batches for gene therapy trials was studied. A complete downstream process comprising three steps-depth filtration, ultra/ diafiltration and membrane sorption-was successfully developed. Optimal operational conditions for each individual step were achieved yielding a scalable DSP for rBVs as vectors for gene therapy. The processing route designed hereby presents global recovery yields reaching 40% (at purities over 98%) and, most importantly, relies on technologies easy to transfer to process scales under cGMP guidelines.
Introduction
Recombinant baculovirus (rBV) has emerged as a novel vector for in vivo and in vitro gene delivery. 1 Indeed, applications of baculovirus-mediated gene transfer have widely expanded to drug screening, eukaryotic gene display, cancer therapy and tissue engineering. 2 In addition, rBV envelope can be used for protein/peptide display rendering rBVs the potential as a vaccine delivery platform. 1, 3 Current efforts to improve rBVs as gene delivery vehicles for mammalian cells are motivated by their advantages over existing gene transfer vectors; for example, nonpathogenicity to mammalian hosts, ability to accommodate very large foreign DNA inserts and reliable production at high titers using insect cell lines. 4, 5 However, the baculovirus distinct properties, in particular surface heterogeneity and nonspherical, rodshaped structure, represent major challenges in the development of robust downstream strategies to produce clinical grade preparations. Moreover, in vivo clinical applications require high doses of viral vectors to achieve the targeted therapeutic effect and effective removal of contaminants because these can inhibit transduction efficiency or can initiate host immune responses leading to unwanted adverse effects. Thus, these challenges on potency and quality urge for the development of efficient and scalable purification and concentration methods to optimize the production of rBVs. 1 The literature is scarce on what concerns the concentration/purification of rBVs as compared to other viral vectors. Routinely, rBVs are purified and concentrated by a series of centrifugation and ultracentrifugation steps after harvesting from cell culture. 6 However, ultracentrifugation protocols are time and labor consuming often leading to significant loss of infectivity (potency) probably due to irreversible aggregation of the viral particles; hence, low recovery yields with low reproducibility are typically obtained. 7 A purification strategy combining ultracentrifugation and size exclusion chromatography has been proposed but the overall recovery yield obtained barely reaches 25%. 8 A concentration step based on the electrostatic surface charge of rBV using cation-exchange ligands was also described. 9, 10 Recently, the concentration of biotinylated rBV vectors using magnetic beads was reported with success. 11 Nevertheless, for applications requiring nonconjugated rBV vectors, there is still no fully scalable downstream processing (DSP) strategy available.
Animal cell-culture-derived impurities such as host cell DNA, host cell protein and endotoxins are major concerns when a clinical application is envisaged. 12 The available purification protocols for rBVs barely address these issues. Viral vectors involved in a large number of clinical trials, for instance, adenoviruses or retroviruses require a combination of DSP steps (concentration, capture and polishing) capable of decreasing these contaminants to acceptable values. [12] [13] [14] [15] The aim of this study was the development of a simple, robust and cost-effective DSP strategy for rBV purification. An efficient purification process mostly based on membrane technology was devised where processing times and validation costs were significantly reduced compared to existing methodologies, thus streamlining the technology transfer to cGMP operations. The DSP strategy presented herein is divided into three major parts: (1) clarification by depth filtration, followed by (2) concentration by cross-flow ultradiafiltration and (3) purification using anion-exchange membrane adsorbers emerging as an alternative for purification of rBV, with great potential for large-scale manufacturing.
Results and discussion

Clarification and concentration
The clarification of the rBV bulk was performed using two depth filters in series: a 3 mm pore size followed by 0.65 mm pore size. A recovery of infective particles (IP) of 95±5% was obtained. This two-stage mode technology allows for the removal of the centrifugation step, while maintaining the product stream sterile as the filters are autoclavable. Furthermore, the filters are easy to use and represent a low up-front capital investment. The typical sequence used for most of the initial clarification steps in cell line-based processes is 0.45 followed by 0.2 mm retention to prevent contamination; however, as rBVs are very large, 16 larger pore sizes were chosen to reduce eventual viral coagulation and retention in the filters. Moreover, the selected pore size allowed for a more effective utilization of the entire depth of the porous filter for rBVs. 17 Concentration of rBVs and removal of low molecular weight contaminants was performed using tangential flow filtration (TFF); this is a technique routinely used at large scale to concentrate and purify viral products. 14 The best retentate flow rates and transmembrane pressure (TMP) operating conditions were determined aiming at an optimized utilization of the membrane while reducing membrane fouling and consequent product loss (Figure 1a) . A TMP of 1.2 bars was selected, because for higher values a tendency for stabilization of the permeate flux occurred for the three different retentate flow rates tested. This stabilization of the permeate flux occurs most probably due to gel layer formation, which may explain the decrease in rBV recoveries. Nevertheless, when operated at the TFF optimized conditions, recovery yields of 70 ± 5% (based on infective rBV titers) were obtained; moreover, concentration factors of, at least, up to 6 were feasibly achieved. Higher concentration factors are likely to be accomplished if one could further control the resilient gel layer formation; in fact, this seems to be the most critical issue, as it has been recently reported that rBVs resist well to other factors such as shear stress. 18 Because at this point the purity did not meet the quality requirements for use in in vitro (or in vivo) clinical testing, the product was conditioned for a next downstream process step, an ion-exchange process. The relationship between increasing diafiltration volumes (DVs) and the amount of total protein removed and recovery yield obtained when using continuous diafiltration was thus also evaluated ( Figure 1b) . From these results, it is possible to conclude that 2 DVs is a good compromise between purity and recovery yield; after reaching a maximum around 2 DVs, a steep decrease is observed for the recovery yield for higher DVs accompanying the total protein content decrease (Figure 1b) . The reproducibility of this technique was also investigated with rBVs from different batches for different applications (Table 1) . These results indicate that, independent of the batch or the method used for infective titer determination, the recovery yield obtained was within the same order of magnitude confirming process robustness. The recovery yields obtained do not differ much from the recoveries reported in the literature when cation-exchange chromatography or ultracentrifugation steps were used to concentrate the virus. (Figure 2 ). UNOSphere Q shows a lower capacity compared to the Capto resins; Cellufine Sulfate does not significantly adsorb rBVs. In addition, as it can be seen, rBV stability was not an issue as no significant rBV titer decrease was observed in the control beaker. As the main objective here was to select a ligand to proceed with the process development, diethylaminoethyl (DEAE) seemed to be a reasonable choice.
Membrane chromatography has been applied with success for virus purification; 20,21 therefore, we investigated the performance of membrane adsorbers using the same DEAE functional group. rBV samples previously clarified by depth filtration and concentrated by TFF were loaded onto Sartobind D MA 75 for comparison against Capto DEAE resin packed in a column bed (10 ml column volume). Three elution steps were defined: (1) 48 mS cm À1 , (2) 73 mS cm À1 and (3) 120 mS cm
À1
. The chromatogram profiles obtained are shown in Figure 3 .
The step elution mode provides a higher concentration factor and allows for the use of higher flow rates and column loads. Although two well-resolved peaks were observed in both experiments, the western blot analysis using a monoclonal antibody (mAb) anti-gp64 envelope protein (the major rBV enveloped protein) indicated that both fraction pools contain rBVs (data not shown). This can be due to the different interactions taking place between the heterogeneous viral surface and the matrix. However, in terms of recovery yields and processing time, the Sartobind D membrane adsorber showed improved performance when compared to Capto DEAE resin in packed bed; indeed, the recovery yield of total rBV particles was around 20% higher using the membrane process.
The loss of rBVs in the flow-through and wash pools suggested that the residence time of the rBV feedstock load on the membrane unit could have been too short to allow full adsorption (data not shown); thus, a recirculation strategy was also evaluated for the membrane adsorber. An rBV sample was recirculated for 30 min at 10 membrane volumes per minute (MV min
) and flow-through samples were withdrawn over time for analysis by western blot (Figure 4 ). After 6 min of recirculation (roughly corresponding to two membrane passages), gp64 was no longer detectable in the flowthrough, indicating that the recirculation mode did not significantly improve the adsorption kinetics of rBV and consequent recovery yield of baculovirus. One should highlight that a low amount of material was used as feedstock to remain well below the maximum binding capacity of the matrix (see below for dynamic binding capacity estimation) to assess only the adsorption dynamics. Alternatively, we decided to reduce the loading flow rate (down to half of the initial flow rate used) to allow the same residence times.
To fully characterize the membrane anion-exchange chromatography matrix, its dynamic binding capacity for rBVs was measured using a sample previously clarified and concentrated using the methodologies described above; the rBV sample was loaded onto a Sartobind D MA 15 unit ( Figure 5 ). A flow rate of 5 ml min À1 was used and viral particles were analyzed by qPCR. The breakthrough curve demonstrates that the dynamic binding capacity for rBVs, at these dynamic conditions and at 10% breakthrough, is approximately 7.7 Â 10 10 TP ml
, or per membrane effective area, 8.5 Â 10 8 TPcm
À2
; further, up to 70 ± 5% of the bound virus can be eluted with addition of Dulbecco's phosphate-buffered saline (D-PBS) supplemented with 600 mM NaCl.
The purified rBVs samples were also analyzed using SDS-polyacrylamide gel (SDS-PAGE) ( Figure 6 ). The profile obtained with the membrane strategy (lane 4) is comparable to rBVs purified by sucrose gradient ultracentrifugation (lane 5) showing even higher purity; several bands disappeared in the SDS-PAGE pattern when the Sartobind D process was used.
To assess the eligibility for clinical purposes, DNA levels and endotoxin contents of purified samples were assessed. Endotoxin levels of end-product samples were below 10 EU ml
À1
, that is, of sufficient purity, whereas the amount of host-cell-derived dsDNA was approximately 2 mg per 10 9 TP. However, this value can be significantly decreased if an additional operation specifically aimed at reducing DNA is incorporated, for Purification of baculoviruses for gene therapy T Vicente et al example, by adding a nuclease incubation step or DNA precipitation. 22 To further characterize the rBV samples obtained after purification with the membrane adsorber, dynamic light scattering (DLS) was used to estimate the hydrodynamic size of the particles; bovine serum albumin (BSA) and trimers of gp64 (obtained as described elsewhere 23 ) were used to serve as comparison entities (internal controls) against rBV particles coming from sucrose gradient purification and from the proposed purification strategy (Figure 7a ). These results show that rBVs purified using the strategy described are comparable with the size obtained from the classical sucrose gradient purified rBV sample. A two-modal distribution of sizes can be observed that is most likely due to the rod-shaped geometry of the rBV particles. The extended peak observed to almost 800 nm may also be an indication of some aggregation as compared to the expected size of the isolated baculovirus particle of around 300-400 nm in length. Morphological characterization was performed by transmission electron microscopy. As shown in Figure 7b , the purified rBVs consist of intact, rod-shaped Volume (mL) Figure 5 Dynamic binding capacity study from breakthrough curve for the capture of baculovirus from concentrated and diafiltrated supernatant. The sample was loaded onto Sartobind D MA 15 at 5 ml min À1 . C 0 is the initial qPCR titer of recombinant baculovirus (rBV) and C is the qPCR titer of rBV at sampling instant.
Purification of baculoviruses for gene therapy T Vicente et al particles with a size roughly 70 nm Â 320 nm, values slightly lower than the ones obtained with DLS (90-100 nm Â 300-400 nm). However, one must recall that the size determined by DLS is, in fact, an estimation of a hydrodynamic size, that is, with rBVs suspended in buffer conditions; as such, this might lead to some particle swelling as compared to the dried particle observed by transmission electron microscopy.
Upon achieving high purity with the three membrane purification steps, a desalting step was introduced after the anion-exchange membrane process to obtain the rBVs in the desired salt concentration and pH for storage and/or clinical administration. Finally, a 0.2 mm microfiltration was performed to assure sterility of the final product; the infective rBV recovery yields were dramatically dependent on the filters used, which might have been caused by the entrapment of the rod-shaped rBVs particles in the porous membrane. Two different filters were investigated and the best recoveries, 90±10%, were obtained for the filter manufactured with two layers (prefilter of 0.8+0.2 mm membrane) (from Pall, East Hills, NY, USA) as opposed to filters with no prefilter (data not shown). One can circumvent this final sterile filtration drawback by designing a fully closed aseptic process, possible in cGMP operations. However, completely closed processing has its own issues and all of the tools involved may turn the investment capital higher than regular processing.
Summing up, the indicators of the proposed integrated downstream process are presented in Table 2 . A final recovery yield of 38 ± 5% was obtained with a final ratio between total particles and IP below 20. To confirm the gene delivery functionality of the rBVs throughout the complete downstream process, transduction assays were carried out using HepG2 as mammalian testing cells. Figure 8 shows in vitro fluorescence images of targeted cells 24 h after transduction using a lowdilution factor (see rBV transduction assays in Materials and methods section) to guarantee unambiguous positive (or negative) DsRed2 expression signal; that is, with at least 100 plaque-forming units (PFU) per target cell in the positive signal samples. Whereas the flow-through fractions did not induce any positive signal, the supernatant and, especially, the concentrated samples after TFF and eluted peak from Sartobind D showed evidence of bright red fluorescence under green light excitation demonstrating that the rBVs particles are functional throughout the purification process.
Concluding remarks
This work describes a complete and integrated purification scheme for rBVs mostly based on disposable In conclusion, the approach devised here represents a substantial improvement for the production process of clinical grade rBVs.
Materials and methods rBV stock propagation
Sf9 insect cells (ECACC 89070101, UK) were routinely grown in Gibco Sf-900 II SFM (serum-free) culture medium (Invitrogen, Paisley, UK) using spinner (stirred at 150 r.p.m. in a magnetic stirrer) or Erlenmeyer vessels (shaken at 110 r.p.m. in an orbital shaker). Cell concentration and viability were routinely assessed by haemocytometer (Brand, Wertheim, Germany) with cell viability evaluated by 0.4% trypan blue exclusion dye (Merck, Darmstadt, Germany) in PBS.
Infection procedure was carried out using rBV seed stocks kindly provided by Dr Kari Airenne (AIV Institute/UKU, Kuopio, Finland) at multiplicities of infection (MOI) of approximately 0.1 PFU per cell. Two vectors were used: rBV GFPvp39Nterm (encoding for the baculovirus major structural capsid protein, vp39, containing on its N terminus a GFP protein reporter 24 ) referred to as rBV-GFP, and rBV DsRed2-mCherryvp39Nterm (encoding for vp39 fused with mCherry, a cherry-red fluorescent protein, plus an additional mammalian expression cassette composed of a strong mammalian cell promoter, CMV, and DsRed2, a red fluorescent protein) referred to as rBV-cherry-dsred2.
Production of rBV stocks
Stock aliquots of rBV-GFP were produced in Sf9 cells grown in a 25 l working volume wave-bag bioreactor (Wave Europe, Cork, Ireland) using Sf-900 II medium. Sf9 cells were infected at a viable cell concentration at infection of 1-2 Â 10 6 cells per ml using an MOI of 0.1 PFU per cell. Cell viability and cell infection were monitored for 5 days after infection. 25 Quantification of the infected cells during the process was carried out by flow cytometry assessing GFP-expressing cell populations using a CyFlow Space flow cytometer system (Partec, Mü nster, Germany). Data analysis was carried out using the manufacturer acquisition software FlowMax (Partec). The rBV production bulk was harvested when the cell viability reached values of 50%. Infection bulks were clarified either by centrifugation at 1500 g for 20 min or by depth filtration using 3 and 0.65 mm retention Sartopure PP2 filter capsules (Sartorius Stedim Biotech, Göttingen, Germany) detailed in the Downstream processing in Materials and methods section. Clarified aliquots were stored at 4 1C in the dark until further use.
rBV-cherry-dsred2 stock aliquots were produced in 2 l Erlenmeyer flasks incubated at 27 1C orbital shaker at 110 r.p.m. Sf9 infections were carried out for 5 days after infection (when the cell viability reached 50%). Cell infection was monitored using a fluorescence microscope for the detection of the mCherry signal produced.
Downstream processing
Ultracentrifugation-based purification. rBV standards used as reference for purity and recovery yields were obtained following a classical ultracentrifugation-based purification protocol using sucrose gradients as described in the literature. 26 Clarification assays. A clarification scheme was devised based on disposable depth-filter capsules that are easily integrated downstream of the bioreactor apparatus. Sterile tubing (1/4 inch inside diameter) connections were prepared coupling the outlet of the bioreactor to 3 mm retention Sartopure PP2 filter capsules followed by 0.65 mm retention Sartopure PP2 filter capsules in series. Virtually, all large cell particulates/aggregates were removed from the rBV containing supernatant. ) were achieved by using a peristaltic pump (Watson-Marlow, Wilmington, MA, USA) run at room temperature. The depth filters were pre-equilibrated with D-PBS (supplemented with Ca 2+ and Mg 2+ ) (Invitrogen). Samples were collected for analytical purposes before and after the clarification step.
Concentration/buffer exchange assays. As an intermediate purification/concentration process, ultrafiltration combined with diafiltration using tangential crossflow filtration was developed. The cross-flow filtration runs were performed in an automated Ä KTAcrossflow system controlled by the UNICORN software (all from Abbreviation: NA, not assessed. a TP/IP, ratio between total (TP) and infective (IP) rBVs is an indicator of product quality of the outlet of the specified step. b Total amount of rBVs (TP and/or IP) were used for these calculations, that is, by multiplying the specified titer by the total volumetric amount of material. c Based on the fraction between the total amount of infective rBVs in the outlet (used for the subsequent process step) and the total amount of infective rBVs in the feed of the specified step.
Purification of baculoviruses for gene therapy T Vicente et al GE Healthcare, Uppsala, Sweden). The feed, retentate and permeate side pressures as well as the retentate and permeate flow rates were digitally controlled by the equipment software. Hydrosart membranes (200 cm 2 ) with 100 kDa nominal molecular weight cutoff (Sartorius Stedim Biotech) were mounted on the holder and connected to the Ä KTAcrossflow system. Three retentate flow rates were evaluated: 25, 35 and 50 ml min
À1
; at each of these retentate flow rates, a range of TMPs within 0.25-2 bars was screened. In addition, the impact of DVs (number of buffer volumes used for medium exchange) in the permeate protein content was assessed collecting samples throughout the process.
After setting the optimal operational conditions (35 ml min À1 retentate flow rate and TMP of 1.2 bars; see Results and discussion section), a two-step program 
Purification of baculoviruses for gene therapy
T Vicente et al was used: (1) concentration until a desired concentration factor and (2) continuous diafiltration until a desired DV exchanging the spent medium for D-PBS buffer. All ultra/diafiltration runs were interspersed with 1 M NaOH cleaning-in-place sessions, water washes, water flux tests (where flux vs TMP plots are produced to prove membrane stability and performance for further process runs) and D-PBS system equilibration. All these protocols were performed using the program templates available in the UNICORN software package for Ä KTAcrossflow system and modified accordingly. All experiments were performed at room temperature.
Capture assays. A capture step relying on a bind-elute chromatographic step was chosen as the core of the rBV purification process. A preliminary screening of potential sorption chromatographic ligands was performed by simple batch adsorption using equal amounts of resin (5 ml settled material) and rBV supernatant (fivefold diluted in Tris-base buffer (Merck); at pH 8.0) to a total of 10 ml. Beakers containing each resin-type test were shaken in an orbital shaker at 200 r.p.m. for a period of 75 min. Samples were collected throughout the experiment for rBV quantitation. In parallel, a control experiment was carried out using the same amount of fivefold diluted rBVs lacking any resin in suspension. Resins screened included a weak anionexchange resin, Capto DEAE (GE Healthcare), two strong anion-exchange resins, Capto ViralQ (GE Healthcare) and UNOSphere Q (Bio-Rad, California, USA), and an affinitybased resin composed of sulfate groups designed for large particles that can also behave as cation exchanger, Cellufine Sulfate (Chisso Corporation, Tokyo, Japan).
The best results were obtained with DEAE (see Results and discussion section); taking into account the selection of this ligand, a comparison study between two types of chromatography matrices was performed: an anion-exchange membrane chromatography matrix using Sartobind D MA 75 units (Sartorius Stedim Biotech) with 75 cm 2 effective membrane area (equivalent to approximately 2 ml of membrane volume) containing DEAE, and a packed column-based anion-exchange chromatography matrix using Capto DEAE resin. Both matrices were coupled to an Ä KTAexplorer 100 chromatography system controlled with UNICORN software (GE Healthcare), equipped with online UV absorbance cell detector, conductivity meter, pH sensor and a fraction collector. Both matrices were equilibrated with D-PBS before sample loading with amounts of 100 ml of previously ultra/diafiltered rBV supernatants. Flow rates varied from 5 (resin) to 10 ml min À1 (membrane). After sample loading, D-PBS buffer was allowed to pass through the matrices to remove unbound/contaminant material. Elution of the viral peaks was carried out using serial isocratic steps at buffer conductivities of around 48, 73 and 120 mS cm À1 (using D-PBS containing 1.5 M NaCl as the second mixing buffer).
The dynamic binding capacity of Sartobind D was estimated at 5 ml min À1 using a smaller unit, Sartobind D MA 15 (15 cm 2 effective membrane area or approximately 0.4 ml equivalent volume), injecting the same rBV material as above and collecting samples for rBV titration in each fraction. In addition, the impact of residence time was addressed by testing sample load recirculation at 10 MV min À1 ; samples were collected for detection of rBV throughout the recirculation loading process.
After purification with the membrane adsorber units, the rBV fraction pools were submitted to a final desalting step using a standard HiPrep 26/10 desalting column (GE Healthcare). Sterile microfiltration of final material was performed using Acrodisc Syringe Filters with Supor PES Membrane (Pall) or Sartorius Minisart NML (Sartorius Stedim Biotech) before storage at 4 1C in the dark. These experiments were performed at room temperature.
Characterization methods
Total rBV particles titration. The number of genomecontaining particles referred to as total rBV titer (total particles (TP)) was monitored by real-time PCR (qPCR). Viral DNA was extracted and purified with the High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Mannheim, Germany). Purified rBV viral DNA stocks previously quantitated by another validated qPCR method were used as external standard. 27 The wild-type baculovirus ie-1 gene sequence was used as a template for the amplification of a chosen amplicon of 150 bp (protocol adapted from Lo and Chao 28 ). DNA amplifications were carried out using the LightCycler system with Fast Start Master SYBR Green I kit (Roche Diagnostics). For a 20 ml PCR reaction, 10 ml DNA template and 10 ml of master mix were added to each capillary. The master mix was prepared to obtain a final concentration of 4 mM MgCl 2 and 0.5 mM of each primer in each capillary.
Selected primers used for the ie-1 gene amplification were: forward 5 0 -CCCGTAACGGACCTCGTACTT-3 0 and reverse 5 0 -TTATCGAGATTTATTTGCATACAACAAG-3 0 . The PCR program was set to: DNA denaturation for 10 min at 95 1C; standard amplification using 45 three-step cycles: (1) denaturation heating at 95 1C for 30 s, (2) annealing cooling at 63 1C during 5 s and (3) elongation heating at 72 1C for 6 s. Fluorescence data were acquired at the end of the elongation step of each cycle. Data were analyzed using the LightCycler software (Roche Diagnostics) by means of the 'fit points method' described elsewhere. 29 Infective rBV particles titration. Infective virus titers (IP) were determined either with the traditional endpoint dilution assay method 6 (for rBVs-cherry-dsred2) or with a flow cytometer-based assay (for rBVs-GFP) as developed by Kärkkäinen et al. 30 Briefly, the end-point method was carried out with 96-well plates containing 100 ml of cellular suspension at a density of 0.5 Â 10 6 cells per ml incubated for 1 h at 271C. Dilutions of the virus samples were performed serially in culture medium, from 1:10 4 to 1:10
11
, and 100 ml was used to infect the seeded Sf9 cells monolayers after removing the medium from the plate wells. Ten replicates for each dilution were performed in the same plate, and two independent plates were infected for each viral sample. A dilution of 1:10 2 was used as positive control; culture medium was used as negative control. Plates were screened after 7 days for mCherry fluorescence detection under an inverted fluorescence microscope. The 50% tissue-culture infectious dose (TCID 50 ) and consequent PFU (or number of infective particles) were calculated using the equations described elsewhere. 31 
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In the flow cytometric method, 500 ml of Sf9 cell suspension at 1.5 Â 10 6 cells per ml, seeded into 2.2 ml 96-well plates (ABgene Limited, Epsom, UK), were infected with 500 ml of serial rBV sample dilutions. After incubating the plates at 27 1C for approximately 18 h in a shake flask orbital shaker at 420 r.p.m., cell suspensions were directly submitted to flow cytometer analysis using a 96-well plate autosampler (Partec) serially feeding each sample to the flow cytometer for GFP-expressing cell population assessment. 30 The maximum GFP-expressing cell population percentage (corresponding to a nondiluted viral sample) was used as a normalization factor for reliable titer calculation. 30, 32 rBV transduction assays. HepG2 cell line was used as a target cell line for testing of rBV-cherry-dsred2 transduction potency. HepG2 cells were routinely cultured in modified Eagle's medium (MEM) supplemented with 10% fetal bovine serum and grown at 37 1C in a humidified atmosphere equilibrated with 5% CO 2 . For rBV transduction with samples, HepG2 cells were seeded in 12-well plates at approximately 50% confluence; 24 h later the culture medium was depleted from the wells and the cells were washed with cold PBS; rBV samples were either directly added or diluted 1:2 (likewise for all samples) in MEM containing 1% FBS before incubation at 37 1C (with 5% CO 2 ) for 3 h. Negative control wells containing MEM deprived of any viral sample were used. The virus dilution suspensions from each well were then exchanged with MEM (supplemented with 10% FBS) after a brief PBS wash. Transduction was monitored for up to 15 days by cell visualization under an inverted fluorescence microscope coupled with a digital camera.
SDS-PAGE and western blot. Protein profiling of samples collected after each of the purification steps were performed using NuPAGE Novex 4-12% Bis-Tris precast polyacrylamide gels (Invitrogen) using standard running conditions. Visual detection was carried out using SimplyBlue SafeStain (Invitrogen).
Protein transfer onto nitrocellulose membrane was carried out with a semi-dry transfer unit (GE Healthcare); immunochemical detection of baculovirus main envelope glycoprotein, gp64, was carried out using a commercially available mouse mAb against gp64, AcV5 clone, affinity purified (1:2000 dilution; eBioscience, San Diego, CA, USA) followed by incubation with an alkaline phosphatase-conjugated anti-mouse IgG antibody (1:5000 dilution; Sigma-Aldrich, Mü nchen, Germany) and developed using one-step NBT/BCIP (Pierce, Rockford, IL, USA).
SDS-PAGE and western blot band profiles were analyzed by ImageJ software (NIH, Maryland, MD, USA) using an available add-in designed for gel band densitometry quantification and normalization.
Total protein quantification. Total protein content of samples was determined using the BCA protein assay kit (96-well plate protocol) from Pierce following the manufacturer's protocol.
dsDNA quantification. The quantification of total dsDNA content in solution throughout processing was performed using the PicoGreen dsDNA Assay kit (Invitrogen) in 96-well plates according to the manufacturer's instructions. Endotoxin quantification. The endotoxin level in the end products was determined by LAL test using the Limulus Amebocyte Lysate QCL-1000 kit (Cambrex, Walkersville, MD, USA) following the manufacturer's instructions.
Electron microscopy analysis. rBV integrity and morphology were monitored by transmission electron microscopy. Briefly, 3 ml of sample was adsorbed onto a formvar-coated 400-mesh copper grid (Electron Microscopy Sciences, Hatfield, PA, USA) for 60 s. The grid was then soaked in 1% uranyl acetate for 30 s and dried in air at room temperature. The purified samples were examined in a JEM 200 Ex electron microscope (JEOL, Sollentuna, Sweden).
Dynamic light scattering analysis. Hydrodynamic size estimations of sample particles were obtained by DLS using a Zetasizer Nano-ZS Series ZEN3600 equipped with a 633 nm He-Ne laser (Malvern, Worcestershire, UK). Viral samples were diluted 25-to 60-fold in D-PBS; size measurements were performed in semimicro polystyrene, 10 Â 4 mm, cuvettes. BSA (Merck) diluted in D-PBS was used as a control experiment. The rendered experimental correlation functions from DLS were analyzed by the CONTIN method to obtain distributions of decay rate profiles that provided distributions of apparent diffusion coefficient and, consequently, of the apparent hydrodynamic diameter (through the StokesEinstein equation). Replicates with over 20% deviation were neglected. Before data acquisition, the instrument software automatically optimizes operational conditions such as signal attenuation, focal distance and number of scans.
